Heartware - HTWR, HIN - Breakout on Clinical Results

Big news today from HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN) - preliminary clinical trials showed their heart pumps were a success. Among other details, "patient assessment of their own quality of life more than doubled".

Heartware designs and builds compact heart pumps that treat patients suffering from advanced heart failure. Due to the novel design of the devices, patients can be treated without open heart surgery - a major medical advance - and a slam-dunk from a marketing standpoint. I mean, given the choice, who wouldn't want to avoid open heart surgery?

HTWR has been in my portfolio for more than a year. I bought it on a breakout and once it had shown some profits I transitioned from a resistance-based exit to a 7-ATR trailing stop, which has kept me in the trade through several months of choppy trading.

More from heartware.com.au: Heart failure is a degenerative, terminal disease affecting over 20 million patients worldwide. HeartWare expects to treat an increasing proportion of heart failure patients and to access patients at an earlier stage of their disease progression.  HeartWare's lead product, the HeartWare Ventricular Assist System, has been approved for sale in the European Union and is currently the subject of a clinical trial in the United States. Key features of HeartWare's technology platform include:

• "Wearless" Suspension Mechanism - no points of mechanical contact within the pump, effectively ensuring a "wearless" system.... expected to lead both to longer term device reliability and to a reduced risk of physical damage to blood cells as they pass through the pump. 
• Miniaturization  Reduced procedural invasiveness is expected to lead to more rapid post operative recovery and improved patient outcomes. 
• Optimal Blood Flow Paths A key clinical requirement - cause minimal damage to the blood in the form of either thrombus (blood clotting) or hemolysis (rupturing of blood cell membranes).The HVAD^TM Pump employs a proprietary "wide bladed" impeller, designed to provide optimal blood flow paths through the system. 

Don't try to guess how far a stock can move up. If you do not give your stocks a lot of room to move upward, you will guarantee that your stock market profits will be below average. -Braden Glett

Related Posts

• Trend-following Heartware International - HTWR
• Why many Investors Lose Money
• Why all-time highs outperform
• Trend-trading Potash Corp 2006-2008
• Trade with Focus
• On Setting Stops

Trend view: EW, NRGP, HTWR, KRA

Edwards Lifesciences (EW) and Inergy Holdings (NRGP) continue marching higher and raising their stops. Heartware International (HTWR) has also found support and has been moving up. Trend-following can be boring: I don't know what will happen next, but I do know there are no sell signals, so I should sit on my hands and look at stock screens. KRA has also been doing well since my last post (here).

Related Posts:

• Using Wolfram Alpha to Select Stocks
• Trendview last week
• Learning from the Past: Trend-trading Potash Corp 2006-2008
• Do All Time High Stocks Outperform? Research suggests they do.